相关实验视频

Updated: May 15, 2025

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

如何管理流感危急病患者的抗病毒药物?

Pierre Bay¹, Ignacio Martin-Loeches², Anne-Fleur Haudebourg³

¹Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor-Albert Chenevier, Service de Médecine Intensive Réanimation, Créteil Cedex, France; Groupe de Recherche Clinique CARMAS, Université Paris Est-Créteil, Créteil, France; INSERM U955, Institut Mondor de Recherche Biomédicale, Créteil, France; INSERM U955, Team Viruses, Hepatology, Cancer, Créteil, France.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

|April 9, 2025

概括

在重症患者中治疗严重流感的抗病毒疗法有限. 奥塞尔塔米维尔是常见的,但缺乏强有力的证据在这个人群中,需要进一步研究有效的治疗选择.

科学领域:

关键护理医学关键护理医学
传染病传染病传染病
药理学药理学是指药理学的学科.

背景情况:

流感构成重大威胁,导致大量的发病率和死亡率,特别是在重症患者中.
有效的抗病毒治疗对于控制严重流感和预防并发症至关重要.

研究的目的:

审查在重症患者中治疗严重流感的可用抗病毒药物.
评估优化重症监护室 (ICU) 抗病毒策略的证据强度.

主要方法:

在PubMed,Embase和Cochrane图书馆进行全面的文献搜索,截至2025年1月.
包括关键词:抗病毒疗法,流感,危急病患者,奥塞塔米维尔,佩拉米维尔,扎纳米维尔,拉尼马维尔,巴洛克萨维尔,法维皮拉维尔.
对临床试验,观察性研究和指导方针的审查.

主要成果:

神经氨基酶抑制剂,主要是奥塞尔塔米维尔,主导着流感抗病毒处方.
在重症患者中oseltamivir疗效的证据有限,没有随机对照试验.
在ICU环境中,关于oseltamivir的药理动力学和耐药性 (例如,A(H1N1) pdm09) 的数据很少.

结论:

目前在重症患者中治疗严重流感的抗病毒选择不足.
在这个人群中缺乏对oseltamivir和其他抗病毒药物 (zanamivir,peramivir,laninamivir,baloxavir) 的稳健的临床试验数据.
进一步的研究对于开发和评估新药和澄清奥塞塔米维尔在严重流感中的作用至关重要.

关键词:

抗病毒药物是一种抗病毒药.流感是一次流感.在重症监护病房的重症监护病房.神经氨基酶抑制剂的神经氨基酶抑制剂奥塞尔塔米维尔 (oseltamivir) 是一种

更多相关视频

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

相关概念视频

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....